These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36211462)

  • 1. Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer.
    Wang L; Ji XB; Wang LH; Qiu JG; Zhou FM; Liu WJ; Wan DD; Lin MC; Liu LZ; Zhang JY; Jiang BH
    Front Cell Dev Biol; 2022; 10():1008088. PubMed ID: 36211462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-137-regulated AKT serine/threonine kinase 2 inhibits tumor growth and sensitizes cisplatin in patients with non-small cell lung cancer.
    Lu Z; Wang M; Wu S; Ye M; Lin Z; Shun T; Duan C
    Oncol Lett; 2018 Aug; 16(2):1876-1884. PubMed ID: 30008879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1.
    Zhu H; Yang J; Yang S
    Exp Ther Med; 2020 Mar; 19(3):1797-1805. PubMed ID: 32104235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9.
    Wu L; Pu X; Wang Q; Cao J; Xu F; Xu LI; Li K
    Oncol Lett; 2016 Feb; 11(2):945-952. PubMed ID: 26893673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1.
    Ma Z; Cai H; Zhang Y; Chang L; Cui Y
    Biochem Biophys Res Commun; 2017 Aug; 490(2):309-316. PubMed ID: 28619508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retracted Article: CircRNA PVT1 modulates cell metastasis
    Yan L; Bai M; Xu J; Li X; Wu C; Zhou Y; Yan J; Zhang Z
    RSC Adv; 2019 Dec; 9(72):42324-42334. PubMed ID: 35542851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
    Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
    Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-223 regulates autophagy associated with cisplatin resistance by targeting FBXW7 in human non-small cell lung cancer.
    Wang H; Chen J; Zhang S; Zheng X; Xie S; Mao J; Cai Y; Lu X; Hu L; Shen J; Chai K; Chen W
    Cancer Cell Int; 2020; 20():258. PubMed ID: 32577098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum: MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment.
    Song N; Li P; Song P; Li Y; Zhou S; Su Q; Li X; Yu Y; Li P; Feng M; Zhang M; Lin W
    Front Cell Dev Biol; 2020; 8():746. PubMed ID: 32974332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
    Xing S; Qu Y; Li C; Huang A; Tong S; Wu C; Fan K
    J Cell Physiol; 2019 Dec; 234(12):22657-22665. PubMed ID: 31111480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2.
    Chen MJ; Wu DW; Wang GC; Wang YC; Chen CY; Lee H
    Oncotarget; 2018 Mar; 9(17):13758-13767. PubMed ID: 29568392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: MicroRNA-16-1-3p Represses Breast Tumor Growth and Metastasis by Inhibiting PGK1-Mediated Warburg Effect.
    Ye T; Liang Y; Zhang D; Zhang X
    Front Cell Dev Biol; 2021; 9():649787. PubMed ID: 33553193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495/NRF2.
    Li C; Fan K; Qu Y; Zhai W; Huang A; Sun X; Xing S
    J Cell Physiol; 2020 Apr; 235(4):3721-3730. PubMed ID: 31583720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN.
    Ren P; Gong F; Zhang Y; Jiang J; Zhang H
    Tumour Biol; 2016 Mar; 37(3):3215-25. PubMed ID: 26432332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LINC00852 is associated with poor prognosis in non-small cell lung cancer patients and its inhibition suppresses cancer cell proliferation and chemoresistance via the hsa-miR-145-5p/KLF4 axis.
    Tuo Z; Liang L; Zhou R
    J Gene Med; 2021 Dec; 23(12):e3384. PubMed ID: 34342374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
    Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
    Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: Negatively regulated by miR-29c-3p, MTFR1 promotes the progression and glycolysis in lung adenocarcinoma via the AMPK/mTOR signalling pathway.
    Li Y; Liu Y; Jin K; Dong R; Gao C; Si L; Feng Z; Zhang H; Tian H
    Front Cell Dev Biol; 2022; 10():870313. PubMed ID: 36120573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2.
    Cao J; He Y; Liu HQ; Wang SB; Zhao BC; Cheng YS
    Int J Clin Exp Med; 2015; 8(8):12397-403. PubMed ID: 26550150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.